Mablink presents at the digital Next Generation Bioconjugates Summit (November 2-5, 2020)
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …